Tozorakimab Medicine 04 June 2026 Extended indication Tozorakimab monotherapy for treatment of symptomatic Chronic obstructive pulmonary disease in adults and elderly with history of COPD exacerbations. Therapeutic value Total cost Registration phase Clinical trials Product Active substance Tozorakimab Domain Lung diseases Reason of inclusion New medicine (specialité) Main indication COPD Extended indication Tozorakimab monotherapy for treatment of symptomatic Chronic obstructive pulmonary disease in adults and elderly with history of COPD exacerbations. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer AstraZeneca Portfolio holder Mechanism of action Interleukin inhibitor Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Extramural (GVS) Centre of expertise Additional remarks IL-33 binding antibody Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date June 2026 Expected Registration November 2027 Orphan drug Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Tijdslijn op basis van IHSI-inschatting. Therapeutic value Current treatment options Therapeutic value Substantiation Duration of treatment Frequency of administration Dosage per administration References (NCT05158387), OBERON (NCT05166889), MIRANDA (NCT06040086), and PROSPERO (NCT05742802). Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References CBS, https://goldcopd.org/ Additional remarks In Nederland hebben circa 600.000 volwassenen een vastgestelde diagnose COPD. 30 tot 40% van de COPD-patiënten heeft meer dan een matige of ernstige exacerbatie per jaar. Expected cost per patient per year Cost € 13,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Additional remarks Kosten op basis van IHSI-inschatting, afgeleid van de mediane kosten van dezelfde ATC-klasse (L04AC - interleukineremmers) geneesmiddelen in Nederland. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks